Authors' recommendations: Capsaicin patch (Qutenza®) is not recommended for use alone for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults. Capsaicin patch (Qutenza®) is recommended as an option for restricted use within NHS Wales for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults in combination with other medicinal products for pain and in patients who have not received adequate benefit from, or are intolerant to, alternative conventional treatments. The company submission provided evidence on the cost effectiveness of capsaicin patch (Qutenza®) as an add-on treatment in patients who were refractory to or intolerant of usual first or second line treatments. Capsaicin patches (Qutenza®) should be administered by healthcare professionals who have completed the approved training and in a specialist clinic setting. AWMSG is of the opinion that capsaicin patch (Qutenza®) is suitable for specialist only prescribing within NHS Wales for the above indication.

Project Status: Completed

Year Published: 2012

URL for published report: http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=187451&pid=24773

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Wales, United Kingdom

Organisation Name: All Wales Medicines Strategy Group

Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX

Contact Name: AWTTC@wales.nhs.uk

Contact Email: AWTTC@wales.nhs.uk

Copyright: AWTTC